Instalab ResearchMost clinicians use high-sensitivity C-reactive protein (hs-CRP) to gauge inflammation, but newer research shows that TNF-alpha and interleukin-6 (IL-6) can provide distinct, and often superior, information about what’s really happening in the body.
Mechanistic differences matter. TNF-alpha and IL-6 are upstream cytokines, immune signaling molecules that initiate and propagate inflammation. In contrast, hs-CRP is a downstream acute-phase protein made by the liver in response to IL-6. Because of this, TNF-alpha and IL-6 rise within hours of an inflammatory trigger, while hs-CRP peaks one to two days later. This timing makes cytokines better at detecting early or transient inflammatory events (Wunderle et al., Journal of Inflammation, 2025; Marchiori et al., Diagnosis, 2024).
From a prognostic standpoint, IL-6 and TNF-alpha often outperform hs-CRP. IL-6 is a stronger predictor of mortality and cardiovascular events, even when hs-CRP is included in the model (Ferreira et al., Atherosclerosis, 2024; Ridker et al., European Heart Journal, 2020). Both cytokines are linked to chronic kidney disease, stroke severity, and neuropsychiatric symptoms after COVID-19, conditions where hs-CRP alone is less informative (Lee et al., BMC Nephrology, 2015; Ferrando et al., Journal of Psychiatric Research, 2025; Băcilă et al., Life, 2025).
This doesn’t make hs-CRP obsolete. It remains a reliable general marker of systemic inflammation. But combining hs-CRP with IL-6 and TNF-alpha yields a richer immunometabolic profile, improving early detection and refining risk assessment (Marchiori et al., Diagnosis, 2024; Fiedorczuk et al., International Journal of Molecular Sciences, 2023; Zhao et al., Scientific Reports, 2025).
If you’re tracking inflammation to assess chronic disease risk or intervention response, consider measuring both cytokines and hs-CRP. Together, they reveal not just the presence of inflammation, but its origin, timing, and clinical impact.
